BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

...2011 deal with GlycoMimetics Inc. (NASDAQ:GLYC) and returned to the biotech rights to rivipansel, a pan-selectin...
BioCentury | Nov 11, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

...the adhesion of sickled red blood cells (RBCs) and inflammation in patient vasculature, including the pan-selectin...
BioCentury | Nov 9, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

...the adhesion of sickled red blood cells (RBCs) and inflammation in patient vasculature, including the pan-selectin...
BioCentury | Aug 6, 2019
Clinical News

Next up for GlycoMimetics after tanking in sickle cell disease

...YE20. After hours Friday, GlycoMimetics Inc. (NASDAQ:GLYC) said that a Phase III trial of its pan-selectin...
BioCentury | Jul 6, 2018
Emerging Company Profile

Tethering bleeding risk

...With a mechanism that blocks thrombosis-contributing cells but not coagulation, Tetherex Pharmaceuticals Inc.’s pan-selectin inhibitor SelK2...
...trial of crizanlizumab in sickle cell disease also gives the team some confidence for the pan-selectin...
...“pretty significant interest from large pharma.” COMPANY PROFILE Tetherex Pharmaceuticals Inc. Oklahoma City, Okla. Technology: Pan-selectin...
BioCentury | Apr 20, 2018
Financial News

Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

Tetherex Pharmaceuticals Inc. (Oklahoma City, Okla.) said it closed a $50 million series B round on April 18 led by existing investor MPM Capital. I2E, Tetherex board member Philip Jones and other undisclosed Oklahoma-based investors...
BioCentury | Apr 18, 2018
Financial News

Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

Tetherex Pharmaceuticals Inc. (Oklahoma City, Okla.) said it closed a $50 million series B round Wednesday led by existing investor MPM Capital. I2E, Tetherex board member Philip Jones and other undisclosed Oklahoma-based investors also participated....
BioCentury | Nov 29, 2012
Cover Story

Multitasking E selectin

...has activity on other members of the family. GlycoMimetics holds patents covering GMI-1070 and related pan-selectin...
BioCentury | Nov 8, 2012
Distillery Therapeutics

Indication: Hematology

...and leukocyte numbers compared with Sele expression. In wild-type mice receiving chemotherapy, pretreatment with the pan-selectin...
...with saline pretreatment. Ongoing work includes designing SELE-specific antagonists and optimizing for bioavailability. GMI-1070, a pan-selectin...
...doi:10.1038/scibx.2012.1160 Published online Nov. 8, 2012 Multiple issued and pending patents covering GMI-1070 and related pan-selectin...
BioCentury | May 14, 2012
Emerging Company Profile

Visionary: Sights on drug design

...million in upfront and milestone payments, plus royalties. Visionary also is developing a class of pan-selectin...
...hopes to enter the clinic in 2013. Revotar Biopharmaceuticals AG also is developing an inhaled pan-selectin...
Items per page:
1 - 10 of 23